Amicus Therapeutics Inc (FOLD NASDAQ) stock market data APIs
$7.9887
0(0%)
as of October 17, 2025
Try our APIs with
free plan!
Amicus Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company's commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease. It has collaboration and license agreement with GlaxoSmithKline to develop and commercialize Galafold. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
Prev. Close
7.9887
Open
7.9887
High
8.0691
Low
7.8871
52 wk Range
5.51-12.65
Market Cap
2 346 M
Shares Outstanding
308 M
Revenue
571 M
EPS
0.01
Beta
0.528
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Amicus Therapeutics Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Amicus Therapeutics Inc data using free add-ons & libraries
Get Amicus Therapeutics Inc Fundamental Data
Amicus Therapeutics Inc Fundamental data includes:
- Net Revenue: 571 M
- EBITDA: 32 949 K
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-07-31
- EPS/Forecast: -0.11
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Amicus Therapeutics Inc News
New
FDA Extends Review of DNLI's Hunter Syndrome Drug by Three Months
Denali Therapeutics Inc. DNLI announced that the FDA has extended its review timeline of the Biologics License Application (“BLA”) for pipeline candidate, tividenofusp alfa. The BLA is seeking ac...
Bayer Reports Positive Data on Cell Therapy for Parkinson's Disease
Bayer AG’s BAYRY wholly owned, independently operated subsidiary BlueRock Therapeutics LP announced positive 36-month data from an early-stage study of bemdaneprocel, an investigational cell therapy...
What Does Wall Street Think About Amicus Therapeutics (FOLD)?
Amicus Therapeutics, Inc. (NASDAQ:FOLD) is one of the best biotech stocks with high potential. On September 18, Needham analyst Gil Blum upgraded the rating on Amicus Therapeutics, Inc. (NASDAQ:FOLD) ...
All You Need to Know About Amicus Therapeutics (FOLD) Rating Upgrade to Strong Buy
Investors might want to bet on Amicus Therapeutics (FOLD), as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in earnings est...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
